Contact us for free information or to start a free case review.
The filing of the first nationwide Zyprexa class action lawsuit has been announced against Zyprexa maker Eli Lilly and Company. The Zyprexa class action lawsuit represents all U.S. Zyprexa users. The most popular atypical antipsychotic mediation, Zyprexa has been linked to dangerous adverse effects including diabetes, hyperglycemia, and pancreatitis.
In 2003, the FDA requested Eli Lilly update the Zyprexa labeling to include hyperglycemia and diabetes warnings following a 2002 Duke University study showing a link between diabetes and Zyprexa. The British Medical Control Agency and the Japanese Health and Welfare Ministry have also issued warnings because of the reports of diabetes.
Zyprexa sales are still growing, with an increase of 15 percent to $1.1 billion in the first quarter. A third of Eli Lilly''s total global sales are attributed to Zyprexa, and in 2003, Zyprexa was the world''s third best selling drug with $4.8 billion in revenue. The outcome of Zyprexa lawsuits could greatly affect Eli Lilly''s financial condition because of the large impact Zyprexa has on its total revenue.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.